Showing results (21-30 of 112) with videos related to
Sort By:
Pageof 12
Terapevticheskii Arkhiv|December 21, 2020
[Nephrotoxicity of anti-angiogenesis drugs]K S Grechukhina, N V Chebotareva, T N KrasnovaTerapevticheskii Arkhiv|October 26, 2022
[Diagnostic and treatment difficulties in kidney damage in the patient with generalized sarcoidosis during COVID-19. Case report]M V Lebedeva, N V Chebotareva, V D BeketovTerapevticheskii Arkhiv|October 26, 2022
[The Rehberg-Tareev test in assessing the glomerular filtration rate]I N Bobkova, E S Kamyshova, N V ChebotarevaTerapevticheskii Arkhiv|February 1, 2019
The role of podocytes dysfunction in chronic glomerulonephritis progressionN V Chebotareva, I N Bobkova, L V LysenkoTerapevticheskii Arkhiv|July 26, 2002
[Clinical significance of expression of the smooth muscle actin-alpha and CD34 antigen in mesangial cells in glomerulonephritis]N V Chebotareva, D Proppe, P Rudolf, et al.Klinicheskaia Meditsina|October 4, 2002
[Abdominal emergencies in systemic vasculitis]O G Krivosheev, E N Semenkova, S V GuliaevTerapevticheskii Arkhiv|December 30, 2023
[State-of-the-art paradigm of corticosteroid therapy for immune-mediated inflammatory kidney diseases]N M Bulanov, I N Bobkova, S V MoiseevArkhiv Patologii|February 21, 2018
[The clinical and morphological characteristics of C1q glomerulopathy]V A Varshavsky, A N Grishina, N V Chebotareva, et al.Terapevticheskii Arkhiv|July 27, 2011
[Estimation of podocyte dysfunction by nephrinuria severity in proteinuric forms of chronic glomerulonephritis]N V Chebotareva, I N Bobkova, L V Kozlovskaia, et al.Terapevticheskii Arkhiv|October 26, 2022
[Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs]K S Grechukhina, N V Chebotareva, L G Zhukova, et al.Pageof 12